Neuroprotective gene therapy in the aging brain

Autores
Pardo, Joaquín; Morel, Gustavo Ramón; Pereyra, Andrea Soledad; López León, Micaela; Brown, Oscar Alfredo; Bellini, María José; Goya, Rodolfo Gustavo; González Burgos, Ignacio
Año de publicación
2014
Idioma
inglés
Tipo de recurso
parte de libro
Estado
versión publicada
Descripción
Aging is associated with a progressive increase in the incidence of neurodegenerative diseases in both laboratory animals and humans. In the central nervous system, cholinergic and dopaminergic (DA) neurons are among the cells most susceptible to the deleterious effects of age. Thus, the basal forebrain cholinergic system is known to undergo moderate neurodegenerative changes during normal aging as well as severe atrophy in Alzheimer’s disease (AD). Parkinson's disease (PD), a degeneration of nigro-striatal DA neurons is the most conspicuous reflection of the vulnerability of DA neurons to age. Overall, there is growing evidence that a progressive decline in cognitive function and central DA activity represents basic features of normal aging both in humans and laboratory rodents. Exacerbation of these processes contributes to the symptoms of AD and PD, respectively. In this context, neurotrophic factors that can prevent or delay the decline in cognitive function and central DA activity during normal aging may reveal new therapeutic avenues for treatment of AD and PD and are therefore of clinical interest. Among the peptide factors, Insulin-like Growth Factor I (IGF-I) and Glial cell line-Derived Neurotrophic Factor are emerging as powerful neuroprotective molecules for the treatment of neurodegenerative pathologies. Among the neurosteroids, estrogens are recognized as neuroprotective and seem to act synergistically with IGF-I and possibly other neurotrophic peptides. This chapter will discuss the evidence supporting the neuroprotective relevance of the above factors.
Instituto de Investigaciones Bioquímicas de La Plata
Materia
Ciencias Médicas
Envejecimiento
Enfermedad de Alzheimer
Terapia génica
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/151083
Acceder
id SEDICI_a3eee941e396295bb5eec8e719e6529a
oai_identifier_str oai:sedici.unlp.edu.ar:10915/151083
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling Neuroprotective gene therapy in the aging brainPardo, JoaquínMorel, Gustavo RamónPereyra, Andrea SoledadLópez León, MicaelaBrown, Oscar AlfredoBellini, María JoséGoya, Rodolfo GustavoGonzález Burgos, IgnacioCiencias MédicasEnvejecimientoEnfermedad de AlzheimerTerapia génicaAging is associated with a progressive increase in the incidence of neurodegenerative diseases in both laboratory animals and humans. In the central nervous system, cholinergic and dopaminergic (DA) neurons are among the cells most susceptible to the deleterious effects of age. Thus, the basal forebrain cholinergic system is known to undergo moderate neurodegenerative changes during normal aging as well as severe atrophy in Alzheimer’s disease (AD). Parkinson's disease (PD), a degeneration of nigro-striatal DA neurons is the most conspicuous reflection of the vulnerability of DA neurons to age. Overall, there is growing evidence that a progressive decline in cognitive function and central DA activity represents basic features of normal aging both in humans and laboratory rodents. Exacerbation of these processes contributes to the symptoms of AD and PD, respectively. In this context, neurotrophic factors that can prevent or delay the decline in cognitive function and central DA activity during normal aging may reveal new therapeutic avenues for treatment of AD and PD and are therefore of clinical interest. Among the peptide factors, Insulin-like Growth Factor I (IGF-I) and Glial cell line-Derived Neurotrophic Factor are emerging as powerful neuroprotective molecules for the treatment of neurodegenerative pathologies. Among the neurosteroids, estrogens are recognized as neuroprotective and seem to act synergistically with IGF-I and possibly other neurotrophic peptides. This chapter will discuss the evidence supporting the neuroprotective relevance of the above factors.Instituto de Investigaciones Bioquímicas de La PlataResearch Signpost2014info:eu-repo/semantics/bookPartinfo:eu-repo/semantics/publishedVersionCapitulo de librohttp://purl.org/coar/resource_type/c_3248info:ar-repo/semantics/parteDeLibroapplication/pdfhttp://sedici.unlp.edu.ar/handle/10915/151083enginfo:eu-repo/semantics/altIdentifier/isbn/978-81-308-0550-4info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-09-29T11:38:52Zoai:sedici.unlp.edu.ar:10915/151083Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-09-29 11:38:52.914SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv Neuroprotective gene therapy in the aging brain
title Neuroprotective gene therapy in the aging brain
spellingShingle Neuroprotective gene therapy in the aging brain
Pardo, Joaquín
Ciencias Médicas
Envejecimiento
Enfermedad de Alzheimer
Terapia génica
title_short Neuroprotective gene therapy in the aging brain
title_full Neuroprotective gene therapy in the aging brain
title_fullStr Neuroprotective gene therapy in the aging brain
title_full_unstemmed Neuroprotective gene therapy in the aging brain
title_sort Neuroprotective gene therapy in the aging brain
dc.creator.none.fl_str_mv Pardo, Joaquín
Morel, Gustavo Ramón
Pereyra, Andrea Soledad
López León, Micaela
Brown, Oscar Alfredo
Bellini, María José
Goya, Rodolfo Gustavo
González Burgos, Ignacio
author Pardo, Joaquín
author_facet Pardo, Joaquín
Morel, Gustavo Ramón
Pereyra, Andrea Soledad
López León, Micaela
Brown, Oscar Alfredo
Bellini, María José
Goya, Rodolfo Gustavo
González Burgos, Ignacio
author_role author
author2 Morel, Gustavo Ramón
Pereyra, Andrea Soledad
López León, Micaela
Brown, Oscar Alfredo
Bellini, María José
Goya, Rodolfo Gustavo
González Burgos, Ignacio
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Ciencias Médicas
Envejecimiento
Enfermedad de Alzheimer
Terapia génica
topic Ciencias Médicas
Envejecimiento
Enfermedad de Alzheimer
Terapia génica
dc.description.none.fl_txt_mv Aging is associated with a progressive increase in the incidence of neurodegenerative diseases in both laboratory animals and humans. In the central nervous system, cholinergic and dopaminergic (DA) neurons are among the cells most susceptible to the deleterious effects of age. Thus, the basal forebrain cholinergic system is known to undergo moderate neurodegenerative changes during normal aging as well as severe atrophy in Alzheimer’s disease (AD). Parkinson's disease (PD), a degeneration of nigro-striatal DA neurons is the most conspicuous reflection of the vulnerability of DA neurons to age. Overall, there is growing evidence that a progressive decline in cognitive function and central DA activity represents basic features of normal aging both in humans and laboratory rodents. Exacerbation of these processes contributes to the symptoms of AD and PD, respectively. In this context, neurotrophic factors that can prevent or delay the decline in cognitive function and central DA activity during normal aging may reveal new therapeutic avenues for treatment of AD and PD and are therefore of clinical interest. Among the peptide factors, Insulin-like Growth Factor I (IGF-I) and Glial cell line-Derived Neurotrophic Factor are emerging as powerful neuroprotective molecules for the treatment of neurodegenerative pathologies. Among the neurosteroids, estrogens are recognized as neuroprotective and seem to act synergistically with IGF-I and possibly other neurotrophic peptides. This chapter will discuss the evidence supporting the neuroprotective relevance of the above factors.
Instituto de Investigaciones Bioquímicas de La Plata
description Aging is associated with a progressive increase in the incidence of neurodegenerative diseases in both laboratory animals and humans. In the central nervous system, cholinergic and dopaminergic (DA) neurons are among the cells most susceptible to the deleterious effects of age. Thus, the basal forebrain cholinergic system is known to undergo moderate neurodegenerative changes during normal aging as well as severe atrophy in Alzheimer’s disease (AD). Parkinson's disease (PD), a degeneration of nigro-striatal DA neurons is the most conspicuous reflection of the vulnerability of DA neurons to age. Overall, there is growing evidence that a progressive decline in cognitive function and central DA activity represents basic features of normal aging both in humans and laboratory rodents. Exacerbation of these processes contributes to the symptoms of AD and PD, respectively. In this context, neurotrophic factors that can prevent or delay the decline in cognitive function and central DA activity during normal aging may reveal new therapeutic avenues for treatment of AD and PD and are therefore of clinical interest. Among the peptide factors, Insulin-like Growth Factor I (IGF-I) and Glial cell line-Derived Neurotrophic Factor are emerging as powerful neuroprotective molecules for the treatment of neurodegenerative pathologies. Among the neurosteroids, estrogens are recognized as neuroprotective and seem to act synergistically with IGF-I and possibly other neurotrophic peptides. This chapter will discuss the evidence supporting the neuroprotective relevance of the above factors.
publishDate 2014
dc.date.none.fl_str_mv 2014
dc.type.none.fl_str_mv info:eu-repo/semantics/bookPart
info:eu-repo/semantics/publishedVersion
Capitulo de libro
http://purl.org/coar/resource_type/c_3248
info:ar-repo/semantics/parteDeLibro
format bookPart
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/151083
url http://sedici.unlp.edu.ar/handle/10915/151083
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/isbn/978-81-308-0550-4
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research Signpost
publisher.none.fl_str_mv Research Signpost
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1844616263777648640
score 13.070432

Publicaciones similares